This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these template messages)
|
European Institute of Oncology Hospital | |
---|---|
Geography | |
Location | Milan, Italy |
Coordinates | 45°24′51″N9°12′29″E / 45.414194°N 9.208118°E |
Organisation | |
Type | Research hospital |
History | |
Opened | January 1996 |
Links | |
Website | www |
Lists | Hospitals in Italy |
The European Institute of Oncology (Italian : Istituto Europeo di Oncologia, IEO) is a non-profit private-law comprehensive cancer centre located in Milan, Italy. It serves as a clinic, a research centre, and a training institution. IEO is a member of EU-LIFE, an alliance of leading life science research centres in Europe. [1]
The European Institute of Oncology works on the prevention, diagnosis and treatment of cancer by developing clinical and scientific research coupled with organisation and management. It provides a professional network for its members.
The European Institute of Oncology was founded by Umberto Veronesi, who developed a new model for health and advanced research in the international oncology field. [2] The institute was inaugurated in May 1994 and is currently managed by Division and Unit Directors from eight European countries.
The Institute became a research hospital and treatment centre (IRCCS or Istituto di Ricovero e Cura a Carattere Scientifico) through the Ministerial Decree issued in January 1996. The European Institute of Oncology provides services through agreements with Italy’s National Health Service. Professor Gordon McVie performs outreach activities on behalf of the IEO. [3]
The Institute integrates various activities involved in the fight against cancer: prevention and diagnosis, health education and training, research and treatment.
At its centre in Via Ripamonti all clinical, research and training activities take place. In 2002 the institute opened IEO CENTRO, an integrated cancer diagnosis centre in downtown Milan.
Discipline | Science |
---|---|
Language | English, Spanish, Portuguese |
Publication details | |
History | 2007 |
Yes | |
Standard abbreviations | |
ISO 4 | ecancermedicalscience |
Indexing | |
ISSN | 1754-6605 |
Links | |
ecancermedicalscience is the non-profit open-access journal of the European Institute of Oncology. Founded by Professors Umberto Veronesi and Gordon McVie in 2007, ecancermedicalscience is published by Cancer Intelligence and forms part of ecancer.org.
In 2014, Managing Editor Gordon McVie was accepted as a Scholar Member of the World Association of Medical Editors. [4]
ecancermedicalscience is a non-profit journal supported by charitable funding. The key founding charities are The Umberto Veronesi Foundation, the European Institute of Oncology Foundation and Swiss Bridge. [5]
In 2014, ecancermedicalscience became the first open-access journal to charge article fees based on a "pay what you can afford" model. Authors with access to publication funding may donate voluntarily to the journal to cover publication costs. Authors without access to funding do not have to pay any portion of the publishing costs. [6]
In June 2014, a case report published in ecancermedicalscience received international media attention. [7] The case report described a young Latin American girl whose fits of inappropriate laughter were mistakenly diagnosed as misbehavior or demonic possession, but were found to be Gelastic seizures caused by a brain tumor.
ecancermedicalscience is indexed in the following repositories:
A biopsy is a medical test commonly performed by a surgeon, an interventional radiologist, or an interventional cardiologist. The process involves the extraction of sample cells or tissues for examination to determine the presence or extent of a disease. The tissue is then fixed, dehydrated, embedded, sectioned, stained and mounted before it is generally examined under a microscope by a pathologist; it may also be analyzed chemically. When an entire lump or suspicious area is removed, the procedure is called an excisional biopsy. An incisional biopsy or core biopsy samples a portion of the abnormal tissue without attempting to remove the entire lesion or tumor. When a sample of tissue or fluid is removed with a needle in such a way that cells are removed without preserving the histological architecture of the tissue cells, the procedure is called a needle aspiration biopsy. Biopsies are most commonly performed for insight into possible cancerous or inflammatory conditions.
Wilms' tumor or Wilms tumor, also known as nephroblastoma, is a cancer of the kidneys that typically occurs in children, and occurs most commonly as a renal tumor in child patients. It is named after Max Wilms, the German surgeon (1867–1918) who first described it.
Glioblastoma, previously known as glioblastoma multiforme (GBM), is the most aggressive and most common type of cancer that originates in the brain, and has a very poor prognosis for survival. Initial signs and symptoms of glioblastoma are nonspecific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. Symptoms often worsen rapidly and may progress to unconsciousness.
The Union for International Cancer Control or UICC is a non-governmental organisation with some 1,180 member organisations in more than 170 countries.
Umberto Veronesi was an Italian oncologist, physician, scientist, and politician, internationally known for his contributions on prevention and treatment of breast cancer throughout a career spanning over fifty years. He was the founder and president of the Umberto Veronesi Foundation. He also founded and held the role of scientific director and scientific director emeritus of the European Institute of Oncology. During his life and career, Veronesi was awarded a number of prizes for his contributions.
In medicine, an indication is a valid reason to use a certain test, medication, procedure, or surgery. There can be multiple indications to use a procedure or medication. An indication can commonly be confused with the term diagnosis. A diagnosis is the assessment that a particular medical condition is present while an indication is a reason for use. The opposite of an indication is a contraindication, a reason to withhold a certain medical treatment because the risks of treatment clearly outweigh the benefits.
Vaginal cancer is an extraordinarily rare form of cancer that develops in the tissue of the vagina. Primary vaginal cancer originates from the vaginal tissue – most frequently squamous cell carcinoma, but primary vaginal adenocarcinoma, sarcoma, and melanoma have also been reported – while secondary vaginal cancer involves the metastasis of a cancer that originated in a different part of the body. Secondary vaginal cancer is more common. Signs of vaginal cancer may include abnormal vaginal bleeding, dysuria, tenesmus, or pelvic pain, though as many as 20% of women diagnosed with vaginal cancer are asymptomatic at the time of diagnosis. Vaginal cancer occurs more frequently in women over age 50, and the mean age of diagnosis of vaginal cancer is 60 years. It often can be cured if found and treated in early stages. Surgery alone or surgery combined with pelvic radiation is typically used to treat vaginal cancer.
Gynecologic oncology is a specialized field of medicine that focuses on cancers of the female reproductive system, including ovarian cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer. As specialists, they have extensive training in the diagnosis and treatment of these cancers.
Breast-conserving surgery refers to an operation that aims to remove breast cancer while avoiding a mastectomy. Different forms of this operation include: lumpectomy (tylectomy), wide local excision, segmental resection, and quadrantectomy. Breast-conserving surgery has been increasingly accepted as an alternative to mastectomy in specific patients, as it provides tumor removal while maintaining an acceptable cosmetic outcome. This page reviews the history of this operation, important considerations in decision making and patient selection, and the emerging field of oncoplastic breast conservation surgery.
John Gordon McVie was an international authority on the treatment and research of cancer. He wrote over 350 peer-reviewed articles, editorials and books. McVie was born in Glasgow, Scotland and died of non-Hodgkin lymphona and COVID-19 in Bristol, England.
The Society for Immunotherapy of Cancer (SITC), previously known as the International Society for Biological Therapy of Cancer (iSBTc), is a professional society of scientists, academicians, researchers, clinicians, government representatives, and industry leaders from around the world dedicated to improving outcomes in patients with cancer by advancing the science and application of cancer immunotherapy. Currently, SITC has more than 2,400 members, representing 22 medical specialties from 42 countries around the world, who are engaged in the research and treatment of cancer.
Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.
Gustave Roussy is the first leader cancer-research hospital in Europe and ranked among the top 3 best specialized hospitals in the world. It is a centre for high quality patient care, research and teaching. It is highly-known for the treatment of : skin cancers like melanoma, breast cancer, and lung cancer. It provides access to care with many expert doctors who have historically revolutionized the treatment of cancer and contributed to the surge of new molecules in the treatment of cancers and tumors. It is located in the Parisian area. It is named after Gustave Roussy, a Swiss-French neuropathologist.
Robert E. Wittes was Physician-in-Chief of Memorial Sloan-Kettering Cancer Center, from 2002 until December 31, 2012. Prior to his appointment at MSKCC, he was Deputy Director for Extramural Sciences and Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute, where he oversaw NCI's extramural clinical and basic research programs, including the evaluation of new therapeutics, diagnostics, and translational research. Wittes is a fellow of the American College of Physicians, a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Federation for Medical Research. In addition to his institutional affiliations, Dr. Wittes has served as editor-in-chief of the Journal of the National Cancer Institute and Oncology. He has served on the editorial boards of Clinical Cancer Research, Current Opinion in Oncology, The American Journal of Clinical Oncology; Cancer Investigation, and The International Journal of Radiation Oncology-Biology & Physics, among others.
Childhood cancer is cancer in a child. About 80% of childhood cancer cases in high-income countries can be successfully treated via modern medical treatments and optimal patient care. However, only about 10% of children diagnosed with cancer reside in high-income countries where the necessary treatments and care is available. Childhood cancer represents only about 1% of all types of cancers diagnosed in children and adults, It is often more complex than adult cancers with unique biological characteristics and research and treatment is yet very challenging and limited. For this reason, childhood cancer is often ignored in control planning, contributing to the burden of missed opportunities for its diagnoses and management in countries that are low- and mid-income.
Europa Donna – The European Breast Cancer Coalition is an independent non-profit organisation whose members are affiliated groups from 47 countries throughout Europe. The organisation was set up by a group of women from various European countries in 1994. Its head office is in Milan, Italy.
The Association of Cancer Physicians (ACP) is a specialty association in the United Kingdom for medical oncologists. The ACP is recognised by the Royal College of Physicians and the Department of Health, and provides training and regular meetings for members.
Jackson Orem is a physician, medical oncologist and researcher in Uganda. He has served as the director of the Uganda Cancer Institute, since 2004.
The Organisation of European Cancer Institutes (OECI) is an international non-profit organization with European Economic Interest Grouping status. It was created in 1979 to promote greater cooperation among European cancer centers and institutes. Its head office is located in Brussels at the Belgian University Foundation.
The European School of Oncology (ESO) is a provider of continuing medical education to oncology professionals, with a particular focus on areas of Central and Eastern Europe and the Balkans region.